What We're Reading: Page 93
Industry reads hand-picked by our editors
Dec 20, 2022
-
Financial Times
Belgian biotech company Galapagos on the hunt for deals
-
The Washington Post
Weight-loss drugs like Ozempic, Mounjaro, Wegovy gain popularity, effectiveness
-
The Wall Street Journal
Flu, RSV and Covid Drive Demand for Children’s Pain Relievers and Fever Reducers
-
Fierce Pharma
Novartis prunes nearly 300 jobs in Garden State as corporate slimdown rolls on
Dec 19, 2022
-
Axios
Antibiotic, drug shortages highlight America’s supply chain problems — again
-
The New York Times
They Created a Drug for Susannah. What About Millions of Other Patients?
-
Fierce Pharma
After Novo’s Wegovy supply woes, rival Lilly sees shortages for Mounjaro, Trulicity
-
Reuters
Probe of Musk’s Neuralink to scrutinize long-criticized U.S animal welfare regulator
Dec 16, 2022
-
Politico
AbbVie exits the lobby
-
The New York Times
Can a Federally Funded ‘Netflix Model’ Fix the Broken Market for Antibiotics?
-
The Wall Street Journal
Siddhartha Mukherjee on How Cellular Medicine Could Fight Cancer, Diabetes
Dec 15, 2022
-
Stat News
Prisons say they can’t afford to cure everyone with hepatitis C. But some are figuring out a way
-
Fierce Biotech
45 days later, BioCryst abandons another drug, citing competition
-
The Pharma Letter
Novartis to divest five eye drugs to Harrow
-
The Wall Street Journal
Why You Might Be Having Trouble Buying Children’s Flu and Cold Medicine
Dec 14, 2022
-
Fierce Biotech
AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure
-
MIT Technology Review
Neuroscientists have created a mood decoder that can measure depression
-
Bloomberg
Long Covid’s Effects Go Beyond Respiratory Issues
Dec 13, 2022
Dec 12, 2022
-
The Wall Street Journal
The Biotech Takeout Menu Gets Pricier
-
Axios
The growing market for weight loss drugs
-
Financial Times
Immunocore’s Bahija Jallal: ‘There was fantastic science, but without financing, we could not go anywhere’
Previous
